This study was designed to investigate potential resistance mechanisms by studying the expression of resistant genes in 14 fluconazole-resistant Candida albicans isolates, with G487T and T916C mutations in the 14α-demethylase (ERG11) gene, collected from human immunodeficiency virus uninfected patients and a fluconazole-susceptible control strain. The in vitro susceptibilities of the C. albicans isolates to fluconazole were determined using the broth microdilution method and a disc diffusion assay. Expression of Candida drug resistance (CDR)1, CDR2, ERG11, fluconazole resistance (FLU)1 and multidrug resistance (MDR)1 genes was measured using real-time reverse transcription-polymerase chain reaction and evaluated relative to the expression of the control gene 18SrRNA. The CDR1 and CDR2 genes were upregulated in all the fluconazole-resistant C. albicans isolates, whereas only a few isolates showed high expression of MDR1, FLU1 and ERG11 genes compared with the control strain. In conclusion, overexpression of the CDR1 and CDR2 genes may play an important role in fluconazole-resistant C. albicans with G487T and T916C mutations.
DixonDMMcNeilMMCohenML: Fungal infections: A growing threat. Public Health Rep1996; 111: 226–235.
2.
WhiteTCMarrKABowdenRA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev1998; 11: 382–402.
3.
SanglardDOddsFC: Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis2002; 2: 73–85.
4.
SanglardDIscherFKoymansL: Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother1998; 42: 241–253.
5.
JiaXMMaZPJiaY: RTA2, a novel gene involved in azole resistance in Candida albicans. Biochem Biophys Res Commun2008; 373: 631–636.
6.
CalabreseDBilleJSanglardD: A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology2000; 146: 2743–2754.
7.
ChandraJKuhnDMMukherjeePK: Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol2001; 183: 5385–5394.
8.
MaebashiKKudohMNishiyamaY: A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol2002; 46: 317–326.
9.
XuYChenLLiC: Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother2008; 61: 798–804.
10.
National Committee for Clinical Laboratory Standards (NCCLS): Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: Approved Standard, 2nd edn.Wayne, PA: NCCLS, 2002; Vol 28: p M27-A3.
11.
National Committee for Clinical Laboratory Standards (NCCLS): Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Guideline. Wayne, PA: NCCLS, 2004; Vol 29: p M44-A2.
12.
McCulloughMJClemonsKVStevensDA: Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol1999; 37: 417–421.
13.
LivakKJSchmittgenTD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods2001; 25: 402–408.
14.
GiuliettiAOverberghLValckxD: An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods2001; 25: 386–401.
15.
MorschhäuserJBarkerKSLiuTT: The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog2007; 3: e164.
16.
O'ConnorLLahiffSCaseyF: Quantification of ALS1 gene expression in Candida albicans biofilms by RT-PCR using hybridisation probes on the LightCycler. Mol Cell Probes2005; 19: 153–162.
17.
AkbarDHTahawiAT: Candidemia at a University Hospital: Epidemiology, risk factors and predictors of mortality. Ann Saudi Med2001; 21: 178–182.
18.
St-GermainGLaverdièreMPelletierR: Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol2001; 39: 949–953.
19.
BediniAVenturelliCMussiniC: Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect2006; 12: 75–80.
20.
MarichalPKoymansLWillemsensS: Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology1999; 145: 2701–2713.
21.
PodustLMPoulosTLWatermanMR: Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA2001; 98: 3068–3073.
22.
LambDCKellyDESchunckWH: The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem1997; 272: 5682–5688.
23.
KellySLLambDCKellyDE: Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett1999; 180: 171–175.
24.
KellySLLambDCLoefflerJ: The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun1999; 262: 174–179.
25.
LambDCKellyDEWhiteTC: The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother2000; 44: 63–67.
26.
ChenSHShengCQXuXH: Identification of Y118 amino acid residue in Candida albicans sterol 14a-demethylase associated with the enzyme activity and selective antifungal activity of azole analogues. Biol Pharm Bull2007; 30: 1246–1253.
27.
JiangWSTanSSJiangGY: Synergistic effect of terbinafine combined with fluconazole or itraconazole on stable fluconazole-resistant Candida albicans induced by fluconazole in vitro. Chin J Microbiol Immunol2006; 26: 360–364 [in Chinese].
28.
PereaSLópez-RibotJLKirkpatrickWR: Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother2001; 45: 2676–2684.
29.
GoldmanGHda Silva FerreiraMEdos ReisMarques E: Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis2004; 50: 25–32.
30.
RibeiroMAPaulaCR: Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?Diagn Microbiol Infect Dis2007; 57: 71–75.
31.
WhiteTCHollemanSDyF: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother2002; 46: 1704–1713.
32.
MorschhäuserJ: The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta2002; 1587: 240–248.
33.
HolmesARLinYHNiimiK: ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother2008; 52: 3851–3862.
34.
WhiteTC: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother1997; 41: 1482–1487.
35.
MarrKALyonsCNRustadTR: Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother1998; 42: 2584–2589.
36.
LyonsCNWhiteTC: Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother2000; 44: 2296–2303.
